Used in cancer immunotherapy to stimulate the immune system by activating CD40 receptors on antigen-presenting cells. This enhances T-cell activation and promotes anti-tumor responses. Investigated in clinical trials for solid tumors and hematologic malignancies, often in combination with chemotherapy, radiation, or other immunotherapies like checkpoint inhibitors. Shows potential for improving immune recognition and destruction of cancer cells.